Medincell Publishes its Consolidated Annual Financial Results

About this update from Medincell Sa

(April 1 st , 2024 - March 31 st , 2025) Consolidated financial statements for the year 2024-25 (IFRS standards) MONTPELLIER, France, June 17, 2025 --( BUSINESS WIRE )--Regulatory News: Medincell (Paris:MEDCL): Christophe Douat, CEO of Medincell: "2024 marked the beginning of a new era for Medincell with the surge in our revenues notably fueled by the strong performance of UZEDY. Looking ahead, we anticipate further revenue acceleration with the expected 2026 approval and launch our olanzapine LAI, which has first-in-class potential. Building on this momentum, we are executing a growth strategy anchored in three pillars: 1) continuing to engage top-tier partners, 2) focusing on first- and best-in-class LAIs that deliver meaningful impact for patients and strong value for stakeholders, 3) maintaining and strengthening our technological leadership." Stéphane Postic, CFO of Medincell: "With revenue increasing by a factor of 2.8 and operational losses cut in half, we have taken a decisive step toward achieving operational profitability, anticipated for the next fiscal year ending on March 31, 2027. In addition, we have significantly strengthened our balance sheet, enabling us to optimize our financial strategy moving forward. These strong results provide a robust foundation to support our growth ambitions and drive long-term value creation." The audit procedures on the consolidated financial statements are ongoing. Highlights of year UZEDY ® , robust growth momentum in the US (1- and 2-Month Long-Acting Injectable Risperidone, approved by FDA for the treatment of schizophrenia, partnership with Teva) Olanzapine LAI (mdc-TJK) on track for U.S. submission in H2 2025, Europe to follow (Investigational 1-Month Long-Acting Injectable Olanzapine for the treatment of schizophrenia, partnership with Teva) R&D Portfolio progress Strategic co-development and licensing agreement signed with AbbVie (April 2024) Financing Selected financial information for fiscal year 2024-2025 Consolidated cash flow statements (*) The closing balance does not include €12.9 million of low-risk short-term financial investments. A- Net cashflow from operating activities Net cashflow from operating activities was positive this year, thanks to the collection of the $35 million upfront received from AbbVie at partnership execution and of higher royalties from UZEDY ® net sales. This was partially offset by slightly higher operating expenses. B- Net cashflow from investing activities Net cashflow from investing activities include €12.9 million of low-risk short-term investments made by the Company to generate additional financial income from the available cash. Financial income is higher than in previous year (€1.4 million vs €0.6 million) and compensates slightly higher capital expenditures (€0.7 million vs €0.3 million). C- Net cashflow from financing activities The €33.3 million increase over fiscal year closed on March 31, 2025, relates to proceeds of €42.9 million from the capital raise in February 2025 (€39.7 million net of issuance costs). The €25.5 million increase over the previous year related to proceeds of €23.2 million from the capital raise in May 2023, net of issuance costs, and the receipt of the last €10 million tranche of the EIB loan in July 2023. The Company continued to repay its outstanding loans during the fiscal year. Consolidated income statement Revenue and other income: €27.7 million For the year ended March 31, 2025, Company revenues and other income include the following items: Current operating expenses: €38.5 million Current operating expenses increased by €5.6 million (17%) compared to the previous year, showing a good control of their growth. R&D expenses increased from €21.1 million in the previous year to €24.3 million and represented 63% of the total operating expenses. The main drivers explaining this increase are: higher salaries and benefits for the R&D team, higher subcontracting expenses relating to CDMOs and CROs, all of this being partially offset by reduced polymer purchases. Marketing and business development expenses and General and administrative expenses respectively increased by €0.6 million and €1.7 million compared to the previous year, due to higher salaries and benefits. Net financial result: €(7.4) million Net financial loss increased from €(4.0) million to €(7.4) million year-on-year. This variance is mainly explained a €3.5 million non-cash fair value adjustment of the warrants put option granted to the EIB, this adjustment being itself a direct consequence of the strong increase in the Company stock price over the period. Higher debt costs (since Tranche C of the EIB loan did not fully impact the previous year as it was drawn down in July 2023) were offset by higher financial income generated by the Company cash deposits and short-term investments. About Medincell Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable drugs in many therapeutic areas. Our innovative treatments aim to guarantee compliance with medical prescriptions, to improve the effectiveness and accessibility of medicines, and to reduce their environmental footprint. They combine active pharmaceutical ingredients with our proprietary BEPO ® technology which controls the delivery of a drug at a therapeutic level for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, entirely bioresorbable. The first treatment based on BEPO ® technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and is now distributed in the United States by Teva under the name UZEDY ® (BEPO ® technology is licensed to Teva under the name SteadyTeq™). We collaborate with leading pharmaceutical companies and foundations to improve global health through new treatment options. Based in Montpellier, Medincell currently employs more than 140 people representing more than 25 different nationalities. UZEDY ® and SteadyTeq™ are registered trademarks of Teva Pharmaceuticals. www.medincell.com This press release may contain forward-looking statements, particularly concerning the progress of the Company's clinical trials. Although the Company considers that its forecasts are based on reasonable assumptions, any statements other than statements of historical fact that may be contained in this press release relating to future events are subject to change without notice, to factors beyond the Company's control and to the Company's financial capabilities. These statements may include, but are not limited to, any statements beginning with, followed by or including words or expressions such as "objective", "believe", "expect", "aim", "intend", "may", "anticipate", "estimate", "plan", "project", "will", "may", "probably", "should", "could" and other words or expressions of similar meaning or used in the negative. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control which may cause actual results, performance or achievements of the Company to differ materially from those anticipated or implied by such statements. A list and description of such risks, hazards and uncertainties can be found in the documents filed by the Company with the Autorité des Marchés Financiers (AMF) pursuant to its regulatory obligations, including in the Company's document de base, registered with the AMF on September 4, 2018 under number I. 18-062, as well as in documents and reports to be published subsequently by the Company. Furthermore, these forward-looking statements only apply as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, the Company undertakes no obligation to publicly update these forward-looking statements, nor to update the reasons why actual results may differ materially from those anticipated in the forward-looking statements, even if new information becomes available. The Company's updating of one or more forward-looking statements does not imply that it will or will not update these or any other forward-looking statements. This press release is published for information purposes only. The information contained herein does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for securities of the Company in any jurisdiction whatsoever, particularly in France. Similarly, this press release does not constitute investment advice and should not be treated as such. It is not intended to address the investment objectives, financial situation or specific needs of any particular recipient. It should not be relied upon as a substitute for the exercise of your own judgement. All opinions expressed in this document are subject to change without notice. The distribution of this press release may be restricted by law in certain jurisdictions. Persons into whose possession this press release comes are required to inform themselves about and to observe any such restrictions. 1 United States Patent and Trademark Office View source version on businesswire.com: https://www.businesswire.com/news/home/20250617518997/en/ Contacts David Heuzé Head of Corporate and Financial Communications, and ESG [email protected] / +33 (0)6 83 25 21 86 Grace Kim Chief Strategy Officer, U.S. Finance [email protected] / +1 (646) 991-4023 Nicolas Mérigeau / Arthur Rouillé Media Relations [email protected] / +33 (0)1 44 71 94 94 Louis-Victor Delouvrier / Alban Dufumier Investor Relations France [email protected] / +33 (0)1 44 71 94 94

View stock analysis, news, and events for Medincell Sa